Barbara is passionate about science and medicine, with over 27 years of experience at MorphoSys, where she served as both a scientist and executive, in Martinsried Germany and Boston Massachusetts. As Chief Business Officer, she drove growth, strategic partnerships, and closed numerous transactions, generating $2.9bn in revenue.

She led the acquisition and integration of Constellation Pharmaceuticals Inc., strengthening MorphoSys’s oncology leadership, which played a key role in its acquisition by Novartis. A seasoned executive and trusted mentor, she also served on the board of HI-Bio, acquired by Biogen, where she collaborated with top investors to bring treatments to patients with severe autoimmune diseases.

Barbara holds a master of chemistry from University Cologne, a PhD in biochemistry from Medical University Mainz, in cooperation with the Medical Research Center in Cambridge UK, and trained for General Management and Business Administration at Harvard Business School.